|Chemical and physical data|
|Molar mass||145.9 kg/mol|
This drug was created by Raven biotechnologies, which was later acquired by MacroGenics. It was engineered to increase affinity for CD16A polymorphisms and decrease affinity for FcγRIIB (CD16B), an inhibitory receptor.
It is currently in phase 3 clinical trials for combination therapy in metastatic breast cancer in collaboration with Merck. Phase II trials are also in progress for gastric cancer and esophageal cancer.
- Statement On A Nonproprietary Name Adopted By The USAN Council - Margetuximab, American Medical Association.
- "Margetuximab". AdisInsight. Retrieved 1 February 2017.
- Pegram Discusses Promise of Margetuximab/Chemo Combo for HER2+ Breast Cancer. Jan 2017
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|